[Somatostatin analogue treatment in Graves' ophthalmopathy: a case report].
METHODS
The effect of a somatostatin analogue in a patient with Graves' ophthalmopathy is presented, including data on the dose requirements and the results of therapy.


CONCLUSIONS
There are few effective options for the management of Graves' ophthalmopathy, a cell-mediated immune co-morbidity of thyroid disease. Somatostatin analogues inhibit lymphocyte proliferation and activation, and accumulate in the orbital tissue during the active ophthalmopathy. Because of this, such therapy is able to inactivate the ophthalmopathy without complications occurring.
Coloma-González
I
I
Hospital Universitario San Juan de Alicante, Alicante, España. icg_ct@yahoo.es
Mengual-Verdú
E
E
Domínguez-Escribano
J R
JR
Hueso-Abancens
J R
JR
D000328:Adult; D049970:Graves Ophthalmopathy / Q000188:drug therapy*; D006801:Humans; D008297:Male; D010456:Peptides, Cyclic / Q000627:therapeutic use*; D013004:Somatostatin / Q000031:analogs & derivatives* / Q000627:therapeutic use
D010456:Peptides, Cyclic; C060347:lanreotide; D013004:Somatostatin